Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation

被引:37
|
作者
Skidmore, F. M. [1 ]
Drago, V. [2 ]
Foster, P. [2 ]
Schmalfuss, I. M. [3 ]
Heilman, K. M. [2 ]
Streiff, R. R. [1 ]
机构
[1] Univ Florida, Sch Med, N Florida S Georgia VA Med Ctr, McKnight Brain Inst,Dept Med,Div Hematol, Gainesville, FL 32610 USA
[2] Univ Florida, Sch Med, Dept Neurol, Gainesville, FL USA
[3] N Florida S Georgia VA Med Ctr, Serv Radiol, Gainesville, FL USA
来源
关键词
D O I
10.1136/jnnp.2007.120568
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Hereditary aceruloplasminaemia is a disorder of iron metabolism that is characterised by iron accumulation in the brain and other visceral organs. In previously reported cases, individuals with the disorder were noted to have evidence of iron accumulation in the brain. Oral chelating agents have not been used in neurological diseases of iron metabolism. Methods: A 54-year-old woman who presented with ataxia, lower extremity spasticity and chorea was evaluated for evidence of the source of neurological dysfunction. Results: Blood studies revealed no detectable ceruloplasmin. Marked iron overload was defined by a liver biopsy, which showed a variegated pattern consistent with a primary cause of iron overload. Review of MRI scans showed progressive brain atrophy without visible iron accumulation occurring over a 5-year period. The history suggested that neurodegeneration was coincident with aggressive oral iron replacement. Oral chelation improved many symptoms. Conclusions: Our findings in this patient suggest that disorders of iron transport such as aceruloplasminaemia can be a cause of neurological symptoms such as chorea and cognitive decline, as well as progressive neurodegeneration in the absence of visible iron on MRI scans. We found that oral iron chelation was effective at improving symptoms.
引用
收藏
页码:467 / 470
页数:4
相关论文
共 50 条
  • [41] Intra-arterial carboplatin and oral temozolomide for the treatment of progressive metastatic brain tumors
    Newton, HB
    Volpi, C
    Burkart, J
    Bourekas, E
    Christoforidis, G
    Slone, W
    Paleologos, N
    NEUROLOGY, 2006, 66 (05) : A337 - A337
  • [42] SURVIVAL DIFFERENCES IN HEART FAILURE PATIENTS WITH AND WITHOUT IRON DEFICIENCY/ANEMIA AND BY ORAL AND INTRAVENOUS IRON TREATMENT
    Altevers, J.
    Jacob, C.
    Maas, C.
    Krinke, K.
    Barck, I
    Hardt, T.
    Braun, S.
    VALUE IN HEALTH, 2017, 20 (09) : A606 - A606
  • [43] Deferiprone Oral Solution, An Alternative for Early Chelation Therapy In Young Children with Transfusional Iron Overload: A Preliminary Data From A 6-Month Study Period
    Songdej, Duantida
    Sirachainan, Nongnuch
    Wongwerawattanakoon, Pakawan
    Kadegasem, Praguywan
    Chuansumrit, Ampaiwan
    BLOOD, 2011, 118 (21) : 924 - 924
  • [44] Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial
    Kersten, MJ
    Lange, R
    Smeets, MEP
    Vreugdenhil, G
    Roozendaal, KJ
    Lameijer, W
    Goudsmit, R
    ANNALS OF HEMATOLOGY, 1996, 73 (05) : 247 - 252
  • [45] Reachthem: Baseline Characteristics of a 3 Year Prospective Registry of Children with Hemoglobinopathies Receiving Oral Iron Chelators in the Treatment of Transfusional Iron Overload
    Antmen, Bulent
    Karakas, Zeynep
    Oktay, Gonul
    Akin, Mehmet
    Aydogan, Gonul
    Salcioglu, Zafer
    Vergin, Canan
    Unal, Selma
    Organ, Kerem
    Canatar, Aycin
    Koseoglu, Ertan
    Yesilipek, Mehmet Akif
    BLOOD, 2012, 120 (21)
  • [46] THE PROCEEDINGS OF THE 19th INTERNATIONAL CONFERENCE ON CHELATION HELD IN LONDON, UNITED KINGDOM: MAJOR CHANGES IN IRON CHELATION THERAPY IN THE LAST 25 YEARS USING DEFERIPRONE (L1) HAS RESULTED IN THE COMPLETE TREATMENT OF IRON OVERLOAD
    Kontoghiorghes, George J.
    HEMOGLOBIN, 2011, 35 (03) : 181 - 185
  • [47] Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
    Cappellini, M. D.
    Taher, A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2391 - 2402
  • [48] Molecular mechanisms of iron overload-related brain damage in patients with acute ischemic stroke and thrombolytic treatment
    Millan, Monica
    Sobrino, Tomas
    Arenillas, Juan
    Santos, Diego
    Riva, Elena
    Nombela, Florentino
    Silva, Yolanda
    de la Ossa, Natalia Perez
    Moro, Maria Angeles
    Serena, Joaquin
    Castillo, Jose
    Davalos, Antoni
    STROKE, 2007, 38 (02) : 568 - 568
  • [49] OUTCOMES OF A COHORT OF CHILDREN WITH HEMOGLOBINOPATHY RECEIVING ORAL IRON CHELATORS FOR TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN TURKEY: 24-MONTH FOLLOW-UP
    Antmen, B.
    Karakas, Z.
    Kupesiz, O. A.
    Sasmaz, I.
    Kurtoglu, E.
    Aydogan, G.
    Salcioglu, Z.
    Oktay, G.
    Caliskan, U.
    Akin, M.
    Vergin, C.
    Unal, S.
    Kazanci, E. G.
    Timur, C.
    Gumruk, F.
    Tunc, B.
    Irken, G.
    Akkaynak, D.
    Patiroglu, T.
    HAEMATOLOGICA, 2014, 99 : 189 - 189
  • [50] Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial
    Amoushahi, A.
    Sahebkar, A.
    Moeini, P.
    Chitsaz, N.
    MOVEMENT DISORDERS, 2024, 39 : S1 - S1